Morantel allosterically enhances channel gating of neuronal nicotinic acetylcholine α3β2 receptors

Molecular Pharmacology

Volumn 74, Issue 2, 2008, Pages 466-475

  Wu, Tse Yu ^a   Smith, Caleb M ^a   Sine, Steven M ^b   Levandoski, Mark M ^a  

^a GRINNELL COLLEGE   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDRO BETA ERYTHROIDINE; MORANTEL; NEURONAL NICOTINIC ACETYLCHOLINE ALPHA3 BETA2 RECEPTOR; NICOTINIC RECEPTOR;

ALLOSTERISM; ANIMAL CELL; ARTICLE; BINDING SITE; CHANNEL GATING; COMPETITIVE INHIBITION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DESENSITIZATION; FEMALE; NONHUMAN; OOCYTE; PATCH CLAMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR POTENTIAL; XENOPUS LAEVIS;

ALLOSTERIC REGULATION; ANIMALS; ANTHELMINTICS; FEMALE; ION CHANNEL GATING; MORANTEL; NEURONS; RATS; RECEPTORS, NICOTINIC; XENOPUS LAEVIS;

EID: 47949088448     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.044388     Document Type: Article

References (46)

1. Akk G and Steinbach JH (2005) Galantamine activates muscle-type nicotinic acetylcholine receptors without binding to the acetylcholine-binding site. J Neurosci 25:1992-2001.
2. Berrettini WH and Lerman CE (2005) Pharmacotherapy and pharmacogenetics of nicotine dependence. Am J Psychiatry 162:1441-1451.
3. Brejc K, van Dijk WJ, Klaassen RV, Schuurmans M, van Der Oost J, Smit AB, and Sixma TK (2001) Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. Nature 411:269-276.
4. Broad LM, Zwart R, Pearson KH, Lee M, Wallace L, McPhie GI, Emkey R, Hollins-head SP, Dell CP, Baker SR, et al. (2006) Identification and pharmacological profile of a new class of selective nicotinic acetylcholine receptor potentiators. J Pharmacol Exp Ther 318:1108-1117.
5. Cachelin AB and Rust G (1994) Unusual pharmacology of ( + )-tubocurarine with rat neuronal nicotinic acetylcholine receptors containing β4 subunits. Mol Pharmacol 46:1168-1174.
6. Colquhoun D (1998) Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br J Pharmacol 125:924-947.
7. Colquhoun D and Ogden DC (1988) Activation of ion channel in the frog end-plate by high concentrations of acetylcholine. J Physiol Lond 395:131-159.
8. Colquhoun D and Sakmann B (1985) Fast events in single-channel currents activated by acetylcholine and its analogues at the frog muscle end-plate. J Physiol Lond 369:501-557.
9. Colquhoun D and SigworthB (1985) Fitting and statistical analysis of single channel records. In: Single Channel Recording (Sakmann B, Neher E, eds), pp 191-264, Plenum Publishing, New York.
10. Cooper JC, Gutbrod O, Witzemann V, and Methfessel C (1996) Pharmacology of the nicotinic acetylcholine receptor from fetal rat muscle expressed in Xenopus oocytes. Eur J Pharmacol 309:287-298.
11. A receptors supports an allosteric model of modulation. Br J Pharmacol 145:894-906.
12. Fenster CP, Rains MF, Noerager B, Quick MW, and Lester RA (1997) Influence of subunit composition on desensitization of neuronal acetylcholine receptors at low concentrations of nicotine. J Neurosci 17:5747-5759.
13. Ferreri F, Agbokou C, and Gauthier S (2006) Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy. J Psychiatry Neurosci 31:369-376.
14. Fleck MW (2002) Molecular actions of (S)-desmethylzopiclone (SEP-174559), an anxiolytic metabolite of zopiclone. J Pharmacol Exp Ther 302:612-618.
15. Giniatullin R, Nistri A, and Yakel JL (2005) Desensitization of nicotinic ACh receptors: shaping cholinergic signaling. Trends Neurosci 28:371-378.
16. Hansen SB and Taylor P (2007) Galanthamine and non-competitive inhibitor binding to ACh-binding protein: Evidence for a binding site on non-a-subunit interfaces of heteromeric neuronal nicotinic receptors. J Mol Biol 369:895-901.
17. Harvey SC and Luetje CW (1996) Determinants of competitive antagonist sensitivity on neuronal nicotinic receptor beta subunits. J Neurosci 16:3798-3806.
18. A receptors. Mol Neurobiol 18:35-86.
19. Hogg RC and Bertrand D (2007) Partial agonists as therapeutic agents at neuronal nicotinic acetylcholine receptors. Biochem Pharmacol 73:459-468.
20. Hsiao B, Mihalak KB, Repicky SE, Everhart D, Mederos AH, Malhotra A, and Luetje CW (2006) Determinants of zinc potentiation on alpha4 neuronal nicotinic receptors. Mol Pharmacol 69:27-36.
21. Hsiao B, Mihalak KB, Magleby KL, and Luetje CW (2008) Zinc potentiates neuronal nicotinic receptors by increasing burst duration. J Neurophysiol 99:999-1007.
22. Hurst RS, Hajós M, Raggenbass M, Wall TM, Higdon NR, Lawson JA, Rutherford-Root KL, Berkenpas MB, Hoffman WE, Piotrowski DW, et al. (2005) A novel allosteric modulator of the α7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J Neurosci 25:4396-4405.
23. Lee WY and Sine SM (2004) Invariant aspartic Acid in muscle nicotinic receptor contributes selectively to the kinetics of agonist binding. J Gen Physiol 124:555-567.
24. Lee WY and Sine SM (2005) Principal pathway coupling agonist binding to channel gating in nicotinic receptors. Nature 438:243-247.
25. Levandoski MM, Piket B, and Chang J (2003) The anthelmintic levamisole is an allosteric modulator of human neuronal nicotinic acetylcholine receptors. Eur J Pharmacol 471:9-20.
26. Lyford LK, Sproul AD, Eddins D, McLaughlin JT, and Rosenberg RL (2003) Agonist-induced conformational changes in the extracellular domain of α7 nicotinic acetylcholine receptors. Mol Pharmacol 64:650-658.
27. Maelicke A and Albuquerque EX (2000) Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Eur J Pharmacol 393:165-170.
28. Martin RJ (1997) Modes of action of anthelmintic drugs. Vet J 154:11-34.
29. Mathie A, Cull-Candy SG, and Colquhoun D (1991) Conductance and kinetic properties of single nicotinic acetylcholine receptor channels in rat sympathetic neurones. J Physiol 439:717-750.
30. Mitra A, Bailey TD, and Auerbach AL (2004) Structural dynamics of the M4 transmembrane segment of during acetylcholine receptor gating. Structure 12:1909-1918.
31. Ohno K, Wang HL, Milone M, Bren N, Brengman JM, Nakano S, Quiram P, Pruitt JN, Sine SM, and Engel AG (1996) Congenital myasthenic syndrome caused by decreased agonist binding affinity due to a mutation in the acetylcholine receptor epsilon subunit. Neuron 17:157-170.
32. Papke RL and Heinemann SF (1991) The role of the β4-subunit in determining the kinetic properties of rat neuronal nicotinic acetylcholine α3-receptors. J Physiol 440:95-112.
33. Pereira EF, Reinhardt-Maelicke S, Schrattenholz A, Maelicke A, and Albuquerque EX (1993) Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons. J Pharmacol Exp Ther 265:1474-1491.
34. Pereira EF, Alkondon M, Reinhardt S, Maelicke A, Peng X, Lindstrom J, Whiting P, and Albuquerque EX (1994) Physostigmine and galanthamine: probes for a novel binding site on the α4β2 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells. J Pharmacol Exp Ther 270:768-778.
35. Rang HP (1981) Drugs and ionic channels: mechanisms and implications. Postgrad Med J 57 (Suppl 1):89-97.
36. Rayes D, De Rosa MJ, Bartos M, and Bouzat C (2004) Molecular basis of the differential sensitivity of nematode and mammalian muscle to the anthelmintic agent levamisole. J Biol Chem 279:36372-36381.
37. A receptor channels of mouse spinal neurones in culture. J Physiol 475:69-82.
38. Schrattenholz A, Pereira EF, Roth U, Weber KH, Albuquerque EX, and Maelicke A (1996) Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol Pharmacol 49:1-6.
39. Sine SM (2002) The nicotinic receptor ligand binding domain. J Neurobiol 53:431-446.
40. Sine SM, Claudio T, and Sigworth FJ (1990) Activation of Torpedo acetylcholine receptors expressed in mouse fibroblasts: single-channel current kinetics reveal distinct agonist binding affinities. J Gen Physiol 96:395-437.
41. Singhal SK, Zhang L, Morales M, and Oz M (2007) Antipsychotic clozapine inhibits the function of alpha7-nicotinic acetylcholine receptors. Neuropharmacology 52: 387-394.
42. Smulders CJ, Zwart R, Bermudez I, van Kleef RG, Groot-Kormelink PJ, and Vijverberg HP (2005) Cholinergic drugs potentiate human nicotinic alpha4beta2 acetylcholine receptors by a competitive mechanism. Eur J Pharmacol 509:97-108.
43. Unwin N (2005) Refined structure of the nicotinic acetylcholine receptor at 4A resolution. J Mol Biol 346:967-989.
44. Zhang Y, Chen J, and Auerbach A (1995) Activation of recombinant mouse acetylcholine receptors by acetylcholine, carbamylcholine and tetraethylammonium. J Physiol 486:189-206.
45. Zwart R, van Kleef RG, Gotti C, Smulders CJ, and VijverbergHP (2000) Competitive potentiation of acetylcholine effects on neuronal nicotinic receptors by acetylcholinesterase-inhibiting drugs. J Neurochem 75:2492-2500.
46. Zwart R and Vijverberg HP (2000) Potentiation and inhibition of neuronal α3β4 nicotinic acetylcholine receptors by choline. Eur J Biochem 393:209-214.